Axsome Therapeutics to Present at Upcoming Investor Conferences
Sep 18, 2017 11:00 am UTC| Business
NEW YORK, Sept. 18, 2017 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced...
Sep 18, 2017 11:00 am UTC| Business
ALAMEDA, Calif., Sept. 18, 2017 -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of cancer, announced today positive final...
Zephyr Health Expands Zephyr Illuminate Capabilities with Launch of Relationship Analytics
Sep 18, 2017 11:00 am UTC| Business
SAN FRANCISCO, Sept. 18, 2017 -- Zephyr Health, the leading Insights-as-a-Service solution provider for Life Sciences companies, today announced the launch of Relationship Analytics, the latest addition to its...
Alio Gold to Commence Underground Decline and Exploration Program at Ana Paula
Sep 18, 2017 11:00 am UTC| Business
VANCOUVER, British Columbia, Sept. 18, 2017 -- Alio Gold Inc. (TSX:ALO) (NYSE AMERICAN:ALO) (“Alio Gold” or the “Company”), is pleased to announce the board of directors has formally approved an underground exploration...
National Institute on Drug Abuse Awards Pain Therapeutics $2.2 Million Grant
Sep 18, 2017 11:00 am UTC| Business
AUSTIN, Texas, Sept. 18, 2017 -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today announced that it has been awarded a research and development grant from the National Institute on Drug Abuse...
Sep 18, 2017 11:00 am UTC| Business
AUSTIN, Texas, Sept. 18, 2017 -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it has been awarded an approximately $1.8 million research grant from the National Institutes of...
ConverGene Announces Sponsored Research Agreement with MD Anderson
Sep 18, 2017 11:00 am UTC| Business
CAMBRIDGE, Md., Sept. 18, 2017 -- ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s...